Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 3,253 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Head and Neck Cancer, Head Cancer, Neck Cancer
Interventions: RiMO-301, Pembrolizumab, Radiation, Surgical resection; Drug · Radiation · Procedure
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: PTSD - Post Traumatic Stress Disorder
Interventions: Written Exposure Therapy (WET), methylphenidate (MPH), placebo (PBO); Behavioral · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: San Diego, California

Conditions: Weight Maintenance
Interventions: Digital Behavioral Application; Behavioral
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multimorbidity
Interventions: SLIMM - Sit less, interact, move more, PB125; Behavioral · Dietary Supplement
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Bronchitis, Bronchitis, Chronic
Interventions: Glycerol Guiacolate, SOC (Standard of care); Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypogonadism, Male
Interventions: Testosterone Cypionate Injection 200 mg/mL; Drug
Lead sponsor: Azurity Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Birmingham, Alabama • DeLand, Florida • Hialeah, Florida + 3 more

Conditions: Dental Implant
Interventions: Povidone-Iodine; Drug
Lead sponsor: Madigan Army Medical Center; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions: Communication Intervention, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Children With Medical Complexity, Respiratory Tract Infections (RTI), Urinary Tract Infection (UTI), Acute Gastroenteritis, Skin and Soft Tissue Infection
Interventions: Automatic follow-up recommendation, As-needed follow-up recommendation; Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Year to 16 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Bronchopulmonary Dysplasia (BPD), Preterm Birth Complication, Pulmonary, CPAP
Interventions: Nasal CPAP interface: OptiPAP Junior, Nasal CPAP interface: FlexiTrunk; Device
Lead sponsor: Sharp HealthCare; Other
Eligibility: Up to 30 Weeks
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Myocardial Infarction, Coronary Microvascular Disease
Interventions: Coronary angiogram with coronary reactivity testing (CRT); Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Peripheral Arterial Disease, Stenosis, Intermittent Claudication
Interventions: FGF-1, Placebo; Drug
Lead sponsor: Venturis Therapeutics, Inc.; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gastric Cancer, Chemotherapy, Adjuvant, Peritoneal Metastases, Minimally Invasive Surgical Procedures
Interventions: Cisplatin, Doxorubicin; Drug
Lead sponsor: Odense University Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Treatment Resistant Depression, Substance Use Disorders
Interventions: Psilocybin; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Memory Disorders, Mild Cognitive Impairment, Dementia, Social Isolation, Caregiver Burden
Interventions: Social Reminder System; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Keratitis Bacterial, Corneal Ulcer (Diagnosis)
Interventions: Adjunctive Topical Fluorometholone (FML) 0.1%, Standard Topical Antibiotic Therapy; Drug
Lead sponsor: Vishal Jhanji; Other
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Twin to Twin Transfusion Syndrome
Interventions: Curved KARL STORZ fetoscope, Conventional Scopes; Device
Lead sponsor: Jimmy Espinoza; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild, Neuroinflammation, Vascular Contributions to Cognitive Impairment and Dementia (VCID)
Interventions: [11C]PS13: [carbon-11]PS13; COX-1 PET radioligand, Sacubitril-Valsartan; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 50 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Blinatumomab, Revumenib, Lymphoblastic Leukemia, KMT2A-rearranged
Interventions: Revumenib, Blinatumomab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Systemic Sclerosis, Sclerodactyly
Interventions: Hyaluronidase (Hylenex); Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Diagnosis of a Pancreaticobiliary Disorder, Biopsy, EUS Guided Biopsy
Interventions: endoscopic ultrasound guided biopsy with core needle biopsy device, EUS-FNB; Device · Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 89 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Androgenic Alopecia
Interventions: Platelet-rich Plasma Left Side, Platelet-rich Plasma Right Side; Biological
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: HIV (Human Immunodeficiency Virus), Clinical Decision Support System (CDSS), Antiretroviral Therapy, Highly Active, INDIVIDUALIZED THERAPY, AIDS (Acquired Immune Deficiency Syndrome), Personalized Medicine, Precision Medicine
Interventions: smART (Smart Antiretroviral Therapy Assistant), Traditional Prescribing resources; Other
Lead sponsor: Keck School of Medicine of USC; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2028 – 2031
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cardiovascular (CV) Risk, Behavioral Changes, Gardening, Cooking, Nutrition Education
Interventions: GHH Intervention; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Search by objective public record fields.

RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer

Written Exposure Therapy Plus Adjunctive Methylphenidate Treatment for Veterans With PTSD

Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1

Physical Activity Modifies Exercise Responsiveness

Study to Evaluate the Effects of Oral Glyceryl Guiacolate (Guaifenesin, GGE) on Sputum Rheology in Subjects With Mucus Hypersecretion

Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men

Effect of Povidone Iodine on the Dental Implant Internal Surface Microbiome

Adoption of Audio Recording in the Outpatient Supportive Care Center

Automatic Versus As-Needed Follow-up After Hospitalization for Children With Medical Complexity

Parent Perceptions of OptiPAP Junior

A Study of Microcirculatory Function in Type 2 Myocardial Infarction (T2MI)

FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.

Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder

A Mobile Informatics Solution to Assist Caregivers in Care Coordination and Monitoring Social Engagement

Fluorometholone Study

The Efficacy of the KARL STORZ Curved Fetoscope and Straight Fetoscope for Laser Photocoagulation of Placental Anastomoses

[11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction

A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia

Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial

Comparison of FNB to EUS-CNB for Pancreatic Lesions

Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia

Evaluating a Clinical Decision Support Tool for Antiretroviral Therapy Optimization

Growing Healthy Hearts